United Therapeutics (UTHR) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
United Therapeutics (UTHR) has outperformed Zoetis (ZTS) over the past year, gaining 23.3% versus a loss of 47.8%. Over five years, UTHR leads with a +193.6% price change compared with -63.0% for ZTS. Zoetis is the larger company by market cap ($30.91 billion vs $23.55 billion), about 1.3 times the size, while United Therapeutics is growing revenue faster (+10.6% vs +2.3%).
On valuation, Zoetis trades at a lower forward P/E (11.4x vs 16.3x for United Therapeutics). Zoetis pays a dividend yielding 2.75%, while United Therapeutics does not currently pay one. United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus 28.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UTHR | ZTS |
|---|---|---|
| Share price | $549.16 | $74.81 |
| Market cap | $23.55B | $30.91B |
| 1-day change | +3.07% | +2.37% |
| YTD return | +12.71% | -40.54% |
| 1-year return | +23.30% | -47.83% |
| 5-year return | +193.56% | -63.01% |
| P/E ratio (TTM) | 19.67 | 12.03 |
| Forward P/E | 16.25 | 11.43 |
| EPS (TTM) | $27.92 | $6.22 |
| Dividend yield | 0.00% | 2.75% |
| Annual dividend | $0.00 | $2.06 |
| Revenue (latest FY) | $3.18B | $9.47B |
| Revenue growth (YoY) | +10.61% | +2.28% |
| Net income (latest FY) | $1.33B | $2.67B |
| Gross margin | 87.92% | 71.84% |
| Operating margin | 46.89% | — |
| Net margin | 41.94% | 28.23% |
| 52-week high | $609.35 | $148.30 |
| 52-week low | $409.07 | $68.77 |
| Distance from 52-week high | -9.88% | -49.55% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +18.30% | +28.33% |
| Average volume | 678.59K | 5.46M |
| Shares outstanding | 42.89M | 413.22M |
| Employees | 1,400 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UTHR has outperformed ZTS by 71.1 percentage points over the past year.
- United Therapeutics trades at a higher earnings multiple (19.7x vs 12.0x trailing P/E).
- Zoetis offers a meaningfully higher dividend yield (2.75% vs 0.00%).
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus 28.2 cents for Zoetis.
- United Therapeutics grew revenue faster in its latest fiscal year (+10.61% vs +2.28%).
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
UTHR vs ZTS FAQ
Which is bigger, United Therapeutics or Zoetis?
Zoetis (ZTS) is larger, with a market capitalization of $30.91B compared with $23.55B for United Therapeutics (UTHR).
Which stock has performed better over the past year, UTHR or ZTS?
UTHR returned +23.30% over the past 12 months, compared with -47.83% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, UTHR or ZTS?
ZTS has the lower trailing P/E at 12.0, versus 19.7 for UTHR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, United Therapeutics or Zoetis?
Zoetis pays a dividend yielding 2.75%, while United Therapeutics does not currently pay a regular dividend.
Are United Therapeutics and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.